Drug Approval | April 07, 2024
Gland Pharma receives USFDA approval for Eribulin Mesylate Injection
The Product is expected to be the first generic approval on the market
The Product is expected to be the first generic approval on the market
Gland Pharma has reported total income of Rs. 1426.57 crores during the period ended September 30, 2023
The company is committed to address the observations and will submit its response to US FDA within the stipulated time
Gland Pharma has reported total income of Rs. 1246.23 crores during the period ended June 30, 2023
Gland Pharma has reported total income of Rs. 823.95 crores during the period ended March 31, 2023
The United States Food and Drug Administration (USFDA) conducted an inspection at Gland Pharma Limited API Facility at JNPC, Visakhapatnam
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)